RxDoctor Payments Data

Michelle Loubert, DO

Family Medicine · Lansing, MINPI 1245688514

Payments from drug & device makers

$4,844in general payments, 2019–2025

Across 260 payments — averaging $18.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$721
  • Otsuka America Pharmaceutical, Inc.$389
  • Alkermes, Inc.$364
  • Teva Pharmaceuticals USA, Inc.$278
  • Lundbeck LLC$259
  • Pfizer$254
  • plus $3K from 33 others

What the payments were for

  • Food & beverage$4,67597%
  • Education$1683%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,844 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$17,499
Medicare patients
78
Services billed
215

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter79$71,784
OzempicSemaglutide49$52,013
VraylarCariprazine Hcl18$42,067
Breztri AerosphereBudesonide/Glycopyr/Formoterol31$40,715
TrulicityDulaglutide28$35,191
Invega SustennaPaliperidone Palmitate11$29,087
EliquisApixaban18$21,016
FarxigaDapagliflozin Propanediol20$19,576
UbrelvyUbrogepant13$18,675
AuvelityDextromethorphan Hbr/Bupropion12$17,142
TradjentaLinagliptin11$16,107
XareltoRivaroxaban13$13,548
Emgality PenGalcanezumab-Gnlm12$13,100
Stiolto RespimatTiotropium Br/Olodaterol Hcl19$12,674
Spiriva RespimatTiotropium Bromide18$10,217

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$203$71,78479 claims
AbbVieVraylar, Ubrelvy$721$60,74231 claims
AstraZenecaBreztri Aerosphere, Farxiga$58$60,29151 claims
Novo NordiskOzempic$168$52,01349 claims
Johnson & JohnsonInvega Sustenna, Xarelto$121$42,63424 claims
Boehringer IngelheimTradjenta, Stiolto Respimat, Spiriva Respimat$159$38,99848 claims
Lilly USA, LLCTrulicity$218$35,19128 claims
PfizerEliquis$254$21,01618 claims
Axsome Therapeutics, Inc.Auvelity$17$17,14212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →